anvajo closes Series A

Press release: anvajo secures €17.7 million

Dresden-based health tech company anvajo has raised €17.7 million in a Series A round to accelerate the launch of its point-of-care solutions in human medical markets. The financing was led by MEDICE Arzneimittel, with participation from Johnsonville Ventures (US), Elber Beteiligungen, Think.Health, and existing investor Die BrückenköpfeX.

Founded in 2016 as a TU Dresden spin-off, anvajo develops digital diagnostic solutions under the motto: “Detecting diseases early. Truly point of care.” The company’s platform technology reduces the need for multiple devices in near-patient diagnostics, an idea originally driven by founder and CTO Stefan Fraedrich. Flagship products include the vet fluidlab for veterinary urine microscopy and the fluidlab R-300 for research, combining cell counting and spectrometry in one portable device.

anvajo’s innovation has already been recognized with industry awards, including finalist status at the Health-i Awards (Handelsblatt & TK) and first place at the Takeda Innovation Challenge (EIT Health Germany).

With strong investor backing, anvajo is pursuing its mission to connect patients, laboratories, and medical professionals, empowering healthcare through easier access, prevention, and patient-centered diagnostics.